All
Research
Education
Business
Solutions
AR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Türkçe
JA - 日本語
PL - Polski
RU - Русский
HE - עִברִית
AR - العربية
Sign In
Department of Hematology
Angele Kelder has not added Biography.
If you are Angele Kelder and would like to personalize this page please email our Author Liaison for assistance.
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2005 | Pubmed ID: 16166428
Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
Cytometry. Part B, Clinical cytometry Jan, 2008 | Pubmed ID: 18061946
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.
Haematologica Jan, 2009 | Pubmed ID: 19042917
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
Stem cells (Dayton, Ohio) Dec, 2008 | Pubmed ID: 19096043
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML.
European journal of cancer (Oxford, England : 1990) Jun, 2009 | Pubmed ID: 19321337
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
PloS one , 2013 | Pubmed ID: 24244383
High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
Leukemia research Jun, 2014 | Pubmed ID: 24731748
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Pediatric blood & cancer Oct, 2014 | Pubmed ID: 24976003
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
PloS one , 2014 | Pubmed ID: 25244440
VU University medical center
Jacqueline Cloos*,1,2,
Jeffrey R. Harris*,3,
Jeroen J.W.M. Janssen1,
Angele Kelder1,
F. Huang3,
Gerrit Sijm1,
Maike Vonk1,
Alexander N. Snel1,
Jennifer R. Scheick1,
Willemijn J. Scholten1,
Jannemieke Carbaat-Ham1,
Dennis Veldhuizen1,
Diana Hanekamp1,
Yvonne J.M. Oussoren-Brockhoff1,
Gertjan J.L. Kaspers2,4,
Gerrit J. Schuurhuis1,
A. Kate Sasser3,
Gert Ossenkoppele1
1Department of Hematology, VU University Medical Center,
2Pediatric Oncology/Hematology, VU University Medical Center,
3, Janssen Research & Development, LLC,
4, Princess Máxima Center for Pediatric Oncology
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Playlist
Authors
Librarians
Access
ABOUT JoVE
JoVE Sitemap
Copyright © 2025 MyJoVE Corporation. All rights reserved
We use cookies to enhance your experience on our website.
By continuing to use our website or clicking “Continue”, you are agreeing to accept our cookies.
Learn More